Kineticos Life Sciences is a growth and venture investor focused on companies striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. We envision a world without Cancer, Rare and Neurodegenerative Diseases, and Antimicrobial Resistance. Kineticos invests in companies focused on significant, unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. In addition to targeting these disease states and sectors, we look for life science companies utilizing disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, all technologies dramatically changing how medicine is practiced. For more information on Kineticos and its capabilities, please visit www.kineticos.com.